TRAX Financials

Income Statement
MetricQ2 2026
Revenue
0
Cost of Revenue
0
Gross Profit
0
Operating Expenses
34.9M
R&D
25.6M
SG&A
9.3M
Operating Income
-34937000
EBITDA
-34832000
Net Income
-33374000
EPS (Basic)
$-0.95
EPS (Diluted)
$-0.95
Shares (Diluted)
35.0M
MarketsMoversWatchlist
First Tracks Biotherapeutics (TRAX) — Financials